An uncharged oxetanyl sulfoxide as a covalent modifier for improving aqueous solubility

ACS Medicinal Chemistry Letters

Volumn 5, Issue 8, 2014, Pages 900-904

  Skoda, Erin M ^a   Sacher, Joshua R ^a   Kazancioglu, Mustafa Z ^a   Saha, Jaideep ^a   Wipf, Peter ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Aqueous solubility; JP4 039; MMS 350; oxetane; sulfoxide

Indexed keywords

DIMETHYL SULFOXIDE; LITHOCHOLIC ACID; MECLOFENAMIC ACID; MMS 350; NAPROXEN; OXETANE DERIVATIVE; SULFOXIDE; UNCLASSIFIED DRUG;

ACYLATION; AQUEOUS SOLUTION; ARTICLE; COVALENT BOND; DERIVATIZATION; DRUG SOLUBILITY; ESTERIFICATION; IN VITRO STUDY; LIPOPHILICITY; MEMBRANE PERMEABILITY; OXIDATION; PRIORITY JOURNAL;

EID: 84906252082     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5001504     Document Type: Article

References (33)

1. Amidon, G.; Lennernäs, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12, 413-420
2. Baurin, N.; Baker, R.; Richardson, C.; Chen, I.; Foloppe, N.; Potter, A.; Jordan, A.; Roughley, S.; Parratt, M.; Greaney, P.; Morley, D.; Hubbard, R. E. Drug-like annotation and duplicate analysis of a 23-supplier chemical database totaling 2.7 million compounds J. Chem. Inf. Comput. Sci. 2004, 44, 643-651
3. Di, L.; Fish, P. V.; Mano, T. Bridging solubility between drug discovery and development Drug Disc. Today 2012, 17, 486-495
4. Ishikawa, M.; Hashimoto, Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry J. Med. Chem. 2011, 54, 1539-1554
5. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834
6. Wermuth, C. G. Preparation of water-soluble compounds by covalent attachment of solubilizing moieties. In The Practice of Medicinal Chemistry, 3 rd ed.; Wermuth, C. G., Ed.; Elsevier: 2008; pp 767-785.
7. Mouzin, G.; Cousse, H.; Autin, J. M. A new, convenient synthesis of glafenine and floctafenine Synthesis 1980, 54-55
8. Greenwald, R. B. PEG drugs: An overview J. Controlled Release 2001, 74, 159-171
9. Miescher, K.; Fischer, W. H.; Meystre, C. Über Steroide. (33. Mitteilung). Über Glucoside des Desoxycorticosterons Helv. Chim. Acta 1942, 25, 40-42
10. Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Grundmann, M.; Schröder, R.; Hudson, B. D.; Milligan, G.; Cawthorne, M. A.; Kostenis, E.; Kassack, M. U.; Ulven, T. Free fatty acid receptor 1 (FFA1/GPR40) agonists: Mesylpropoxy appendage lowers lipophilicity and improves ADME properties J. Med. Chem. 2012, 55, 6624-6628
11. Wuitschik, G.; Carreira, E. M.; Wagner, B.; Fischer, H.; Parrilla, I.; Schuler, F.; Rogers-Evans, M.; Müller, K. Oxetanes in drug discovery: Structural and synthetic insights J. Med. Chem. 2010, 53, 3227-3246
12. Burkhard, J. A.; Wuitschik, G.; Rogers-Evans, M.; Müller, K.; Carreira, E. M. Oxetanes as versatile elements in drug discovery and synthesis Angew. Chem., Int. Ed. 2010, 49, 9052-9067
13. Lucht, B. L.; Collum, D. B. Etheral solvation of lithium hexamethyldisilazide-unexpected relationships of solvation number, solvation energy, and aggregation state J. Am. Chem. Soc. 1995, 117, 9863-9874
14. Burkhard, J. A.; Wuitschik, G.; Plancher, J.-M.; Rogers-Evans, M.; Carreira, E. M. Synthesis and stability of oxetane analogs of thalidomide and lenalidomide Org. Lett. 2013, 15, 4312-4315
15. Stepan, A. F.; Karki, K.; McDonald, W. S.; Dorff, P. H.; Dutra, J. K.; DiRico, K. J.; Won, A.; Subramanyam, C.; Efremov, I. V.; O'Donnell, C. J.; Nolan, C. E.; Becker, S. L.; Pustilnik, L. R.; Sneed, B.; Sun, H.; Lu, Y.; Robshaw, A. E.; Riddell, D.; O'Sullivan, T. J.; Sibley, E.; Capetta, S.; Atchison, K.; Hallgren, A. J.; Miller, E.; Wood, A.; Obach, R. S. Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors J. Med. Chem. 2011, 54, 7772-7783
16. Stepan, A. F.; Kauffman, G. W.; Keefer, C. E.; Verhoest, P. R.; Edwards, M. Evaluating the differences in cycloalkyl ether metabolism using the design parameter ″Lipophilic Metabolism Efficiency″ (LipMetE) and a matched molecular pairs analysis J. Med. Chem. 2013, 56, 6985-6990
17. Sprachman, M. M. Ph.D. Dissertation, University of Pittsburgh, 2012.
18. Sprachman, M. M.; Wipf, P. A bifunctional dimethylsulfoxide substitute enhances the aqueous solubility of small organic molecules Assay Drug Dev. Technol. 2012, 10, 269-277
19. Rose, N. G. W.; Blaskovich, M. A.; Evindar, G.; Wilkinson, S.; Luo, Y.; Fishlock, D.; Reid, C.; Lajoie, G. A. Preparation of 1-[ N -benzyloxycarbonyl-(1 S)-1-amino-2-oxoethyl]-4-methyl-2,6,7-trioxabicyclo[2.2.2]octane Org. Synth. 2002, 79, 216-227
20. Kurita, K.; Imajo, H. Diphthalimido carbonate: A new reagent for active ester synthesis J. Org. Chem. 1982, 47, 4584-4586
21. Small, D. M.; Admirand, W. Solubility of bile salts Nature 1969, 221, 265-267
22. Hofmann, A. F.; Mysels, K. J. Bile acid solubility and precipitation in vitro and in vivo: The role of conjugation, pH, and Ca2+ ions J. Lipid Res. 1992, 33, 617-626
23. Syed, M. M.; Parekh, A. B.; Tomita, T. Receptors involved in mechanical responses to catecholamines in the circular muscle of guinea-pig stomach treated with meclofenamate Br. J. Pharmacol. 1990, 101, 809-814
24. Avdeef, A.; Bendels, S.; Tsinman, O.; Tsinman, K.; Kansy, M. Solubility-excipient classification gradient map Pharm. Res. 2007, 24, 530-545
25. McNamara, D. P.; Amidon, G. L. Dissolution of acidic and basic compounds from the rotating disk: Influence of convective diffusion and reaction J. Pharm. Sci. 1986, 75, 858-868
26. Kasim, N. A.; Whitehouse, M.; Ramachandran, C.; Bermejo, M.; Lennernäs, H.; Hussain, A. S.; Junginger, H. E.; Stavchansky, S. A.; Midha, K. K.; Shah, V. P.; Amidon, G. L. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharm. 2003, 1, 85-96
27. Bravo-Altamirano, K.; George, K. M.; Frantz, M.-C. l.; LaValle, C. R.; Tandon, M.; Leimgruber, S.; Sharlow, E. R.; Lazo, J. S.; Wang, Q. J.; Wipf, P. Synthesis and structure-activity relationships of benzothienothiazepinone inhibitors of protein kinase D ACS Med. Chem. Lett. 2010, 2, 154-159
28. George, K. M.; Frantz, M.-C.; Bravo-Altamirano, K.; LaValle, C. R.; Tandon, M.; Leimgruber, S.; Sharlow, E. R.; Lazo, J. S.; Wang, Q. J.; Wipf, P. Design, synthesis, and biological evaluation of PKD inhibitors Pharmaceutics 2011, 3, 186-190
29. Rajagopalan, M. S.; Gupta, K.; Epperly, M. W.; Franicola, D.; Zhang, X.; Wang, H.; Zhao, H.; Tyurin, V. A.; Pierce, J. G.; Kagan, V. E.; Wipf, P.; Kanai, A. J.; Greenberger, J. S. The mitochondria-targeted nitroxide JP4-039 augments potentially lethal irradiation damage repair In Vivo 2009, 23, 717-726
30. Frantz, M.-C.; Pierce, J. G.; Pierce, J. M.; Kangying, L.; Qingwei, W.; Johnson, M.; Wipf, P. Large-scale asymmetric synthesis of the bioprotective agent JP4-039 and analogs Org. Lett. 2011, 13, 2318-2321
31. Frantz, M.-C.; Skoda, E. M.; Sacher, J. R.; Epperly, M. W.; Goff, J. P.; Greenberger, J. S.; Wipf, P. Synthesis of analogs of the radiation mitigator JP4-039 and visualization of BODIPY derivatives in mitochondria Org. Biomol. Chem. 2013, 11, 4147-4153
32. Huttunen, K. M.; Raunio, H.; Rautio, J. Prodrugs-from serendipity to rational design Pharmacol. Rev. 2011, 63, 750-771
33. Wipf, P.; Lynch, S. M.; Powis, G.; Birmingham, A.; Englund, E. E. Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system Org. Biomol. Chem. 2005, 3, 3880-3882